SCHEMBL20239342

SCHEMBL20239342

CCc1cnc(NCc2cc(NCc3ccc(OC)cc3)nc(Oc3ccc(CCNS(N)(=O)=O)cc3)c2)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.50
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA9 Q16790 3/20 0.50
CA5A P35218 2/20 0.50
CA14 Q9ULX7 2/20 0.50
ABL1 P00519 1/20 0.40
RIN1 Q13671 1/20 0.40
VNN1 O95497 5/20 0.39
CA4 P22748 1/20 0.39
PTGDR Q13258 1/20 0.38
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
MAP2K7 O14733 1/20 0.37
PTGS2 P35354 1/20 0.36
LMNA P02545 1/20 0.36
DGAT2 Q96PD7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239218 0.88 DGAT2 (0.47) CA12CA1CA2CA9VNN1
SCHEMBL20239275 0.87 CA1 (0.44) CA12CA1CA2CA9CA5A
SCHEMBL20239213 0.86 TAAR1 (0.41) ABL1RIN1VNN1PTGDRNPC1
SCHEMBL28427913 0.86 CA12 (0.46) CA12CA1CA2CA9CA5A
SCHEMBL20239251 0.85 VNN1 (0.44) VNN1SMN1; SMN2KMT2AMAP2K7HDAC1
SCHEMBL20239291 0.85 ACACB (0.42) CA12CA1CA2CA9VNN1
SCHEMBL20472855 0.84 GPR39 (0.44) CA12CA1CA2CA9VNN1
SCHEMBL20259170 0.82 VNN1 (0.41) VNN1KMT2AMAP2K7HDAC1
SCHEMBL20239335 0.81 SLC6A4 (0.43) VNN1PTGDRNPC1RAB9AKMT2A
SCHEMBL20259121 0.80 SMN1; SMN2 (0.45) CA12CA1CA2CA9CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107635975-B DGAT2 inhibitors 伊莱利利公司 2020-07-24 CN disclosed
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT CA12 4871/4885CA1 4849/4885CA2 4773/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT CA12 4871/4885CA1 4830/4885CA2 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.